**Ajanta Pharmaceuticals Q3 Results 2025**
Ajanta Pharmaceuticals announced its Q3 results on January 30, 2025, revealing a year-over-year topline growth of 3.71%. The company’s profit rose by 10.88% YoY, reaching ₹232.88 crore, while revenue totaled ₹1146.13 crore. However, when compared to the previous quarter, revenue declined by 3.41%, although profit increased by 7.58%.
The company’s selling, general, and administrative expenses increased by 1.61% quarter-over-quarter and saw a notable rise of 14.62% year-over-year, indicating higher operational costs. Operating income experienced a decline of 5.81% from the previous quarter and a slight decrease of 0.88% year-over-year. The earnings per share (EPS) for Q3 was ₹18.59, reflecting an 11.52% increase YoY, suggesting positive growth in profitability metrics.
Ajanta Pharmaceuticals has encountered a challenging market environment recently, with a -7.57% return in the last week, a -4.14% return over the past six months, and an -8.71% return year-to-date. As of January 31, 2025, the company’s market capitalization is ₹33,437.09 crore, with a 52-week high of ₹3485 and a low of ₹1998.35.
Analyst sentiment is mixed, with nine analysts covering the company as of January 31, 2025. Among them, two have rated it as a Strong Sell, one as Sell, three as Buy, and three as Strong Buy. The current consensus recommendation is to Buy, reflecting optimism regarding the company’s future performance.
**Ajanta Pharmaceuticals Financials**
| Period | Q3 (FY25) | Q2 (FY25) | Q-o-Q Growth | Q3 (FY24) | Y-o-Y Growth |
|———————-|———–|———–|————–|———–|————–|
| Total Revenue | 1146.13 | 1186.64 | -3.41% | 1105.15 | +3.71% |
| Selling/General/Admin Expenses | 265.17 | 260.96 | +1.61% | 231.35 | +14.62% |
| Depreciation/Amortization | 35.97 | 34.39 | +4.59% | 34.26 | +4.99% |
| Total Operating Expense | 861.27 | 884.21 | -2.59% | 817.76 | +5.32% |
| Operating Income | 284.86 | 302.43 | -5.81% | 287.39 | -0.88% |
| Net Income Before Taxes | 307.39 | 290.24 | +5.91% | 290.91 | +5.66% |
| Net Income | 232.88 | 216.48 | +7.58% | 210.03 | +10.88% |
| Diluted Normalized EPS | 18.59 | 17.26 | +7.71% | 16.67 | +11.52% |
